Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 11Myelodysplastic Syndromes 3Leukemia 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Mastocytosis, Systemic 2Leukemia, Mast-Cell 2Congenital Abnormalities 2Aggression 2Neoplasm, Residual 1Leukemia, Myelomonocytic, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Leukemia, Eosinophilic, Acute 1Leukemia, Basophilic, Acute 1GATA2 Deficiency 1

Interventions

Azacitidine 2midostaurin 1Vorinostat 1Nivolumab 1Lenalidomide 1Injections 1Decitabine 1Cytarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × GATA2 Deficiency × midostaurin × Clear all
NCT03092674 2025-01-16

Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

National Cancer Institute (NCI)

Phase 2/3 Completed
76 enrolled 16 charts
MyeloidOther hematologic neoplasm

GATA2 Deficiency, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡